In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report).

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as ...

Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company ...

“It was always able to filter out at least 85% of the microplastics or even more.” Ou and Huang presented their prototype at the Regeneron International Science and Engineering Fair (ISEF), the ...

Moate Community School student Fionn Campbell is set to present his project ‘A crystal clear way to slow down Ireland’s ...

Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...

Over the summer, BioNTech released Phase 2 data on its mRNA cancer vaccine in the works alongside Regeneron. The vaccine, ...